【新唐人2014年08月14日訊】中共湖南省紀委一名官員，日前在網上實名舉報，中共前國家食品藥品監督管理局局長邵明立，在將中藥「金銀花」改名為「山銀花」的過程中，扮演利益集團的代言人，導致上千萬花農遭受巨大經濟損失。有分析指出，邵明立涉中共活摘器官罪惡，背後有保護傘，總能逃過究責，而舉報者卻屢遭迫害。
8月12號，湖南省紀委預防腐敗室副主任陸群，用實名認證微博賬號「御史在途」，連發13條微博，指稱在邵明立的一手操控下，2005年前後，國家藥典委把中國南方地區傳承上千年的「金銀花」更名為「山銀花」，把「金銀花」作為邵明立老家山東「忍冬花」的專用名。
公開資料顯示，邵明立是山東人，曾任衛生部藥政管理局副局長、局長，國家食品藥品監督管理局副局長，2005年6月升任局長，2008年3月，任衛生部副部長。前年2月，被免去衛生部副部長、國家藥監局局長職務，轉任國家藥典委常務副主任委員。
陸群在微博中說，品質優良的南方金銀花被更名後，價格一落千丈。北方金銀花販子趁機大量低價收購，冒充北方金銀花高價賣出，牟取暴利，而南方上千萬花農則血本無歸。
前湖南藥品公司推銷退休幹部夏先生：「2005年以後，他們更名叫山銀花，醫生不知道，社會不承認，市場不認可，所以我們的金銀花就沒有市場了。」
陸群還說，為了搞垮南方金銀花產業，以山東「九間棚」為代表的無良企業斥巨資公關，先修改國家藥典，再造謠譭謗南方金銀花「上火」。造謠的重慶某文化傳播公司，已經承認收取「九間棚」130萬元的費用。而國家食藥監總局的官員們收了多少黑錢，只有他們自己知道。
陸群表示，他將以鐵的證據，揭露國家藥監局的腐敗問題。
湖南省紀委預防腐敗室副主任陸群：「國家藥監局把南方地區的金銀花修改名字，改成山銀花，他沒任何的依據，你看他公開回應上面說那幾個理由，根本不成立，我會在接下來的第一時間內，我會駁斥他們，證明他們那個是一派謊言，實際上就是國家藥監局各地的官員，他被利益集團操控了，為利益集團代言。這個事情，我都會擺出來的。」
陸群的微博引髮網民熱烈討論。有網友說，事實如何請國家公開調查，給民眾一個交代。還有一些網友擔心陸群的安危，叮嚀他要注意安全。
美國《大紀元》新聞網專欄作者周曉輝指出，事實上，早在國家藥監局前局長鄭筱萸2007年因受賄被處死刑後，邵明立就曾被舉報，舉報者是曾擔任《中國消費者報社》等媒體特約記者的高純。
高純舉報說，鄭筱萸之死掩蓋了邵明立的罪惡，因為沒有人去追究，1995年到國家藥監局成立之前的1998年，國家藥政局局長邵明立是怎樣賣藥品批文的，沒有人去追究，此後國家藥監局到底賣出了多少批文。
西安藥廠推銷員鄒先生：「作為藥監局那些高層來說，他們過去就是濫批藥物，比如說一些藥物，廠家生產出來以後，在一個省內要中標。所以在這個方面就是說，能批下來這個生產許可這類東西，本身應該是很嚴格的，但是他們一天就批幾個或幾天就批一個，這種做法倒是常見。」
周曉輝表示，一系列造成許多人死亡和殘疾的食品藥品事件，都發生在邵明立主政期間，但他卻每每逃脫被追責。到底誰在罩著邵明立？而高純卻因持續舉報，多次遭迫害。
周曉輝透露，邵明立與「瑞士諾華製藥公司」關係密切，與「瑞士羅氏製藥公司」的交集也有跡可尋。而這兩家公司生產的抑制免疫力藥劑，廣被中國的腎移植患者使用。
2005年1月至2006年6月，諾華公司用300人作腎實驗，實驗地點是被懷疑活摘、移植法輪功學員器官的「上海第一人民醫院」。
周曉輝指出，「瑞士諾華製藥」與「羅氏製藥」在中國迅速發展，與中共活摘法輪功學員器官的罪惡是分不開的，而主管藥品審批的邵明立擺脫不了自身的罪惡。
採訪/陳漢 編輯/陳潔 後製/李勇
Real Name Report On Food and Drug Administration Director
A Hunan Provincial Commission for Discipline Inspection
official recently issued a report online regarding former
Director of the State Food and Drug Administration,
Shao Mingli, using his real name.
Shao was said to have played a key role in changing
the name of a famous Chinese herb.
He served as a representative for the herb that replaced
a well-known herb, causing huge economic loss of tens
of millions of growers.
Analysts point out that Shao Mingli has been involved
in the CCP’s organ harvesting.
His umbrella of protection has always helped to him avoid
charges, but the informants are always persecuted.
On Aug. 12, deputy director of the Prevention of Corruption
of Hunan Provincial Commission for Discipline Inspection,
Lu Qun, issued 13 blog statements regarding Shao Mingli
with his real name.
He indicated that Shao changed the name of a southern
Chinese herb, Jin-yin-hua, to San-yin-hua.
Shao also specified the herb to be Jin-yin-hua
in his hometown in Shandong.
Shao Mingli is a Shandong native.
He held various posts at the Ministry of Health
and the state Food and Drug Administration.
In June 2005 he was promoted to Director of the FDA
and in March 2008 he served as Deputy Minister of Health.
In Feb. 2012, he was dismissed from the Ministery of Health
and the FDA, but transferred to the State Pharmacopoeia
Commission as Deputy Chairman.
Lu Qun stated in the blog that after the name change,
the price of good quality Southern Jin-yin-hua plummeted.
Northern traders took the opportunity to acquire the herb
at low cost and sell at high prices as the northern herb.
Tens of millions of southern growers were left to endure
a tremendous economic loss.
Mr. Xia, a retiree from a Hunan drug company:
“Since the herb was renamed in 2005, doctors,
society and the market do not recognize the new name.
Jin-yin-hua was left with no market."
Lu Qun wrote that in order to bring down the Southern
Jin-yin-hua industry, Shandong’s industry spent huge sums
on public relations to change the name through
the national pharmacopoeia.
They then spread rumors to slander the southern Jin-yin-hua
as causing side effects.
A Chongqing public relations company admitted to accepting
a 1.3 million yuan PR fee to publicize the rumors.
The amount of bribery FDA officials have received
is unknown.
Lu Qun indicates that he will expose the corrupt FDA
with solid evidence.
Lu Qun: “The State FDA baselessly renamed the southern
Jin-yin-hua as San-yin-hua.
The publicized responses do not sustain.
I will refute them quickly and prove them lying.
In fact, the entire FDA at local levels has endorsed for local
interest groups and have been controlled by interest groups.
I will show all the evidence."
Lu Qun’s blogs have sparked heated discussion
among netizens.
Some demanded public investigation.
Others worried for Lu Qun’s safety.
The Epoch Times columnist Zhou Xiaohui indicates that as
early as when former Director of FDA Zheng Xiaoyu
was executed for taking bribes in 2007, Shao Mingli had been
reported by a China Consumer News journalist, Gao Chun.
Gao Chun reported that Zheng Xiaoyu’s death has masked
Shao Mingli’s crimes.
Between 1995 and 1998, no one questioned how Director
of FDA Shao Minli approved the sale of the drug.
Mr. Zou, Xi’an pharmaceutical salesman (voice modified):
“The high State FDA officials abused the approval process.
For instance, the manufacturers delivered the drugs
for approval.
The process of getting a license should be very strict.
But, they would just do it randomly, a few in a day
or sometimes one every few days.
It is very common."
Zhou Xiaohui indicates that a series of fatalities and
disabilities caused by food and drug have occurred during
Shao Mingli’s power, but he often escaped being
held accountable.
Who is covering for Shao Mingli while Gao Chun has been
repeatedly persecuted for his persistent reports on Shao?
Zhou Xiaohui reveals that Shao Mingli has close ties
to Novartis Pharmaceuticals.
He also had interactions with the Swiss pharmaceutical
company Roche.
The immunosuppressive agents produced by these two
companies are widely used by China’s kidney transplant patients.
Between January 2005 and June 2006, Novartis conducted
a kidney test on 300 people.
The test was done in Shanghai First People’s Hospital,
a hospital alleged to be engaged in organ harvesting
from living Falun Gong practitioners.
Zhou Xiaohui points out that rapid development of Novartis
and Roche in China is inseparable from the CCP crime’s
of organ harvesting from living Falun Gong practitioners.
Shao Mingli, responsible for the drug approval,
cannot escape from his sins.
Interview/ChenHan Edit/ChenJie Post-Production/LiYong
